Moderna falls in response to latest RSV vaccine efficacy data

Moderna's (NASDAQ: MRNA) stock fell on Wednesday after the latest efficacy data for the newly approved respiratory syncytial virus (RSV) vaccine disappointed Wall Street.

Last month, the US FDA approved a messenger RNA-based vaccine branded as mResVIA to protect adults 60 years and older from lower respiratory disease (LRTD) due to RSV infection.

Ahead of the CDC's Vaccine Advisory Committee meeting to be held this week, Moderna (mRNA) announced on Wednesday that mResvia's vaccine efficacy against two or more LRTD symptoms has reached 50% as of March.

This data was presented at the CDC's Vaccination Implementation Advisory Committee (ACIP), and ACIP refers to the opinions of this committee to determine Mresvia's market development.

GSK (GSK) and Pfizer (PFE) currently dominate the RSV vaccine market. This is because the FDA approved Alexby and Ablisbo, which have been developed conventionally, for the elderly last year.

Jefferies analyst Michael Yee stated that the level of efficacy is the lower limit of expectations for the latest Modena (MRNA) data.